STC2 Is a Potential Prognostic Biomarker for Pancreatic Cancer and Promotes Migration and Invasion by Inducing Epithelial–Mesenchymal Transition.

Aberrant expression of stanniocalcin 2 (STC2) is implicated in cancer development. STC2 acts as a tumor promoter to drive some cancers. However, its contribution to the development of pancreatic cancer remains unclear. This study showed that the expression of STC2 was significantly upregulated in pa...

Full description

Bibliographic Details
Published in:BioMed Research International pp. 1 - 10
Main Authors: Lin, Chen, Sun, Lina, Huang, Shenglei, Weng, Xiangqun, Wu, Zhixian
Format: pictorial research tables/charts Journal Article
Published: Wiley-Blackwell 7/15/2019
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=137483904&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 137483904
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        23146133
        FT2T
      jtl: BioMed Research International
      issn: 23146133
      maglogo: N
    pubinfo:
      dt: 7/15/2019
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        137483904
        137483904
        137483904
        10.1155/2019/8042489
        137483904
      ppf: 1
      ppct: 9
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: STC2 Is a Potential Prognostic Biomarker for Pancreatic Cancer and Promotes Migration and Invasion by Inducing Epithelial–Mesenchymal Transition.
      aug:
        au:
          Lin, Chen
          Sun, Lina
          Huang, Shenglei
          Weng, Xiangqun
          Wu, Zhixian
        affil: Department of General Surgery, Fuzhou General Hospital (Dongfang Hospital), Xiamen University, Fuzhou, Fujian 350025, China
      sug:
        subj:
          Pancreatic Neoplasms Prognosis
          Intercellular Signaling Peptides and Proteins Metabolism
          Intercellular Signaling Peptides and Proteins Physiology
          Biological Markers
          Epithelial Cells Metabolism
          Receptors, Cell Surface Metabolism
          Human
          Gene Expression
          Tumor Burden
          Neoplasm Metastasis Complications
          Survival
          Cancer Patients
          Epithelial Cells Drug Effects
          Intercellular Signaling Peptides and Proteins Adverse Effects
      ab: Aberrant expression of stanniocalcin 2 (STC2) is implicated in cancer development. STC2 acts as a tumor promoter to drive some cancers. However, its contribution to the development of pancreatic cancer remains unclear. This study showed that the expression of STC2 was significantly upregulated in pancreatic cancer tissues. Moreover, its expression was positively correlated with tumor size and lymph node metastasis and negatively correlated with 5-year survival rate of pancreatic cancer patients. Additionally, the expression levels of STC2 were a novel biomarker for predicting overall survival rate after surgery. Furthermore, overexpression of STC2 could promote the proliferation, migration, and invasion of pancreatic cancer cell lines, while knocking down of STC2 led to antiproliferation and antimetastasis activities. Further mechanistic investigations revealed that the expression of STC2 could significantly promote the epithelial–mesenchymal transition (EMT) in pancreatic cancer cells. These data indicated that the overexpression of STC2 in pancreatic cancer contributes to the metastasis through the promotion of EMT, suggesting that STC2 is a potential prognostic biomarker and therapeutic target for pancreatic cancer.
      pubtype: Academic Journal
      doctype:
        pictorial
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N